Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL6009 Target Snapshot

Diacylglycerol O-acyltransferase 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,583Compounds
128Assays
0Approved Drugs
2,228.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Diacylglycerol O-acyltransferase 1 shows clinical signal disease relevance led by Constipation. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O75907. Start with Constipation, then reuse UniProt O75907 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Constipation, then reuse UniProt O75907 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
Constipation

Diacylglycerol O-acyltransferase 1 shows clinical signal disease relevance led by Constipation. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Constipation because it currently carries clinical signal support. Linked drugs include PRADIGASTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Diacylglycerol O-acyltransferase 1 as ChEMBL target CHEMBL6009, mapped to UniProt O75907. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Diacylglycerol O-acyltransferase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL6009
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O75907
Diacylglycerol O-acyltransferase 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Diacylglycerol O-acyltransferase 1 is the right protein anchor across sources, using UniProt O75907 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Constipation is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameDiacylglycerol O-acyltransferase 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO75907
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDiacylglycerol O-acyltransferase 1
UniProt AccessionO75907
Component TypeProtein
Sequence Length488 aa

Diacylglycerol O-acyltransferase 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Diacylglycerol O-acyltransferase 1, mapped to UniProt O75907. Sequence length is 488 aa.

Mapped IDO75907
Review nameDiacylglycerol O-acyltransferase 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Diacylglycerol O-acyltransferase 1 shows clinical signal disease relevance led by Constipation. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
Constipation
1 linked drug · 1 direct · 1 efficacy
Linked drugPRADIGASTAT
Clinical signal Phase II
hepatitis C virus infection
1 linked drug · 1 direct · 1 efficacy
Linked drugPRADIGASTAT
Clinical signal Phase II
non-alcoholic fatty liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugPRADIGASTAT
Clinical signal Phase I
hyperlipoproteinemia
1 linked drug · 1 direct · 1 efficacy
Linked drugPRADIGASTAT
Clinical signal Phase I
kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugPRADIGASTAT
Clinical signal Phase I
liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugPRADIGASTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Constipation because it currently carries clinical signal support. Linked drugs include PRADIGASTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseConstipation
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase III
2
Phase I
Assay Mix

Activity Type Distribution

IC502,163.0
KI17.0
EC5047.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3785201 10.7 Ki 0.02 Preclinical
CHEMBL3896316 10.62 Ki 0.024 Preclinical
CHEMBL3924320 10.33 Ki 0.047 Preclinical
CHEMBL3921693 10.22 Ki 0.06 Preclinical
CHEMBL3901785 10.11 Ki 0.078 Preclinical
CHEMBL3959542 10.11 Ki 0.078 Preclinical
CHEMBL3930993 10.0 Ki 0.101 Preclinical
CHEMBL3786507 9.84 Ki 0.145 Preclinical
CHEMBL5790611 9.52 IC50 0.3 Preclinical
CHEMBL5825430 9.52 IC50 0.3 Preclinical
Distribution

pChEMBL Value Distribution

91
5.0
111
5.5
166
6.0
240
6.5
376
7.0
352
7.5
269
8.0
181
8.5
32
9.0
5
9.5
pChEMBL
Assay Landscape

Assay Landscape

128
Total Assays
1,398
Tested Compounds
1
Assay Types
Binding — 128 assays, 1,398 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 64 597 6.9
single protein format 39 246 7.6
assay format 14 437 7.8
cell membrane format 6 61 6.7
microsome format 3 47 6.6
tissue-based format 2 10 7.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine